OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance

- Q3 revenue of $26.1 million, increased 22% year-over-year- Q3 gross profit increased 30% year-over-year to$ 17.5 million- Increases full year 2025 guidance to a revenue range between $105 million and$ 109 million and adjusted EBITDA range between $16 million and$ 19 million- Introduces 2026 guidance with a revenue range between $118 million and$ 124 million and adjusted EBITDA range between $19 million and$ 22 million- Paid off an incremental $2 million in principal from term loan subsequent to ...